MindMed’s MNMD heated proxy battle over R&D strategy might finally be coming to an end. On Wednesday, June 21, the company announced a preliminary vote assessment that showed shareholders elected all six of its nominees at the annual meeting.
As stated by the psychedelics biotech company, a quorum was present at the annual meeting, and the number of shares represented exceeded 40% of the total outstanding shares entitled to vote.
Following suit, CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone would comprise MindMed’s new board of directors.
MindMed’s CEO and director Robert Barrow thanked both the company’s shareholders “for their support and engagement throughout this process” and independent proxy advisory firms Institutional Shareholder Services (ISS) and Glass, Lewis & Co. “for their recommendations, which validated our strategy and the quality of our directors.”
Further, Barrow stated the board is “fully committed to the company’s success as we navigate this pivotal period,” referring to the two key clinical readouts expected later this year.
“We are glad to put this proxy contest behind us and fully focus on bringing our transformative therapies to market in order to help patients in need and deliver value for all shareholders,” he concluded.
Final results will be filed on a Form 8-K with the U.S. SEC as well as with the Canadian securities regulatory authorities.
Photo: Benzinga edit with photo by Raimundo79 and Blue Planet Studio on Shutterstock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.